Viridian Therapeutics 관리

관리 기준 확인 1/4

Viridian Therapeutics CEO는 Steve Mahoney, Oct2023 에 임명되었습니다 의 임기는 1.08 년입니다. 총 연간 보상은 $ 13.02M, 0.9% 로 구성됩니다. 0.9% 급여 및 99.1% 보너스(회사 주식 및 옵션 포함). 는 $ 432.35K 가치에 해당하는 회사 주식의 0.027% 직접 소유합니다. 432.35K. 경영진과 이사회의 평균 재임 기간은 각각 1.1 년과 4.1 년입니다.

주요 정보

Steve Mahoney

최고 경영자

US$13.0m

총 보상

CEO 급여 비율	0.9%
CEO 임기	1.1yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	1.1yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Nov 14

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22

CEO 보상 분석

Steve Mahoney 의 보수는 Viridian Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$257m
Jun 30 2024	n/a	n/a	-US$228m
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

보상 대 시장: Steve 의 총 보상 ($USD 13.02M )은 US 시장( $USD 5.50M ).

보상과 수익: Steve 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Steve Mahoney (53 yo)

1.1yrs

테뉴어

US$13,022,654

보상

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stephen Mahoney	CEO, President & Director	1.1yrs	US$13.02m	0.027% $ 432.3k
Seth Harmon	Senior VP of Finance and Accounting	1.2yrs	US$6.67m	0.0013% $ 20.2k
Thomas Beetham	Chief Operating Officer	1.1yrs	US$5.17m	0.0076% $ 121.1k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Vahe Bedian	Co-Founder & Scientific Advisor	no data	데이터 없음	데이터 없음
Jennifer Tousignant	Chief Legal Officer	less than a year	데이터 없음	데이터 없음
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Melissa Manno	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음
Anthony Casciano	Chief Commercial Officer	1.6yrs	데이터 없음	데이터 없음
Thomas Ciulla	Chief Medical Officer	1.8yrs	데이터 없음	0.00096% $ 15.4k

1.1yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: VRDN 의 관리팀은 경험 (평균 재직 기간 1.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Stephen Mahoney	CEO, President & Director	1.1yrs	US$13.02m	0.027% $ 432.3k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Arlene Morris	Independent Director	6.8yrs	US$477.83k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Stefanie Dimmeler	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Jeffery Molkentin	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Eva van Rooij	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Tomas Kiselak	Independent Chairperson of Board	4.1yrs	US$503.83k	0% $ 0
Jennifer Moses	Independent Director	3.3yrs	US$467.83k	0% $ 0
Peter Harwin	Independent Director	4.1yrs	US$471.83k	0% $ 0

4.1yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: VRDN 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Viridian Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

CEO, President & Director recently bought US$499k worth of stock

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Recent updates

We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, President & Director recently bought US$499k worth of stock

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Price target increased by 7.5% to US$37.81

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

New minor risk - Share price stability

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

Consensus revenue estimates fall by 19%

First half 2024 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New minor risk - Share price stability

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Price target decreased by 10% to US$41.36

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 18%

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

President recently bought US$101k worth of stock

Consensus revenue estimates fall by 35%

President recently bought US$160k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Price target increased by 9.1% to US$47.08

Chief Medical Officer exercised options and sold US$708k worth of stock

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Consensus revenue estimates increase by 162%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics board compensation committee approves inducement grants

Consensus forecasts updated

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Price target increased to US$39.22

CEO 보상 분석